These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 16999816)

  • 21. Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.
    Reyes HD; Carlson MJ; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Yang S; Stephan JM; Savage EC; Dai D; Goodheart MJ; Leslie KK
    Gynecol Oncol; 2016 Jan; 140(1):152-60. PubMed ID: 26524723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IMMUNOHISTOCHEMISTRY IN ENDOMETRIAL HYPERPLASIA AND ENDOMETRIAL ADENOCARCINOMA.
    Socolov D; Socolov R; Lupascu IA; Rugina V; Gabia O; Garauleanu DM; Carauleanu A
    Rev Med Chir Soc Med Nat Iasi; 2016; 120(2):355-62. PubMed ID: 27483717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The correlation between the response to progestogen treatment and the expression of progesterone receptor B and 17beta-hydroxysteroid dehydrogenase type 2 in human endometrial carcinoma.
    Utsunomiya H; Suzuki T; Ito K; Moriya T; Konno R; Sato S; Yaegashi N; Okamura K; Sasano H
    Clin Endocrinol (Oxf); 2003 Jun; 58(6):696-703. PubMed ID: 12780745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.
    van der Putten LJM; Visser NCM; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Werner HMJ; Amant F; Massuger LFAG; Pijnenborg JMA
    Int J Gynecol Cancer; 2018 Mar; 28(3):514-523. PubMed ID: 29324536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus.
    Bonneterre J; Hutt E; Bosq J; Graham JD; Powell MA; Leblanc E; Fujiwara K; Herzog TJ; Coleman RL; Clarke CL; Gilles EM; Zukiwski AA; Monk BJ
    Gynecol Oncol; 2015 Sep; 138(3):663-7. PubMed ID: 26142884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. L-type amino acid transporter 1 expression increases in well-differentiated but decreases in poorly differentiated endometrial endometrioid adenocarcinoma and shows an inverse correlation with p53 expression.
    Watanabe J; Yokoyama Y; Futagami M; Mizunuma H; Yoshioka H; Washiya K; Hana K; Endou H; Okayasu I
    Int J Gynecol Cancer; 2014 May; 24(4):659-63. PubMed ID: 24694899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of progesterone receptor A and B isoforms in low-grade endometrial stromal sarcoma.
    Balleine RL; Earls PJ; Webster LR; Mote PA; deFazio A; Harnett PR; Clarke CL
    Int J Gynecol Pathol; 2004 Apr; 23(2):138-44. PubMed ID: 15084842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies.
    Akahira J; Inoue T; Suzuki T; Ito K; Konno R; Sato S; Moriya T; Okamura K; Yajima A; Sasano H
    Br J Cancer; 2000 Dec; 83(11):1488-94. PubMed ID: 11076658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progesterone receptor isoform identification and subcellular localization in endometrial cancer.
    Leslie KK; Stein MP; Kumar NS; Dai D; Stephens J; Wandinger-Ness A; Glueck DH
    Gynecol Oncol; 2005 Jan; 96(1):32-41. PubMed ID: 15589577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-associated macrophages, epidermal growth factor receptor correlated with the triple negative phenotype in endometrial endometrioid adenocarcinoma.
    Jiang XF; Tang QL; Shen XM; Li HG; Chen LH; Wang XY; Luo X; Lin ZQ; Jiang GY
    Pathol Res Pract; 2012 Dec; 208(12):730-5. PubMed ID: 23122929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor-associated macrophages correlate with progesterone receptor loss in endometrial endometrioid adenocarcinoma.
    Jiang XF; Tang QL; Li HG; Shen XM; Luo X; Wang XY; Lin ZQ
    J Obstet Gynaecol Res; 2013 Apr; 39(4):855-63. PubMed ID: 23106983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Steroid sulfatase and estrogen sulfotransferase in human endometrial carcinoma.
    Utsunomiya H; Ito K; Suzuki T; Kitamura T; Kaneko C; Nakata T; Niikura H; Okamura K; Yaegashi N; Sasano H
    Clin Cancer Res; 2004 Sep; 10(17):5850-6. PubMed ID: 15355916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coexpression index of estrogen receptor alpha mRNA isoforms in simple, complex hyperplasia without atypia, complex atypical hyperplasia and adenocarcinoma.
    Witek A; Paul-Samojedny M; Stojko R; Seifert B; Mazurek U
    Gynecol Oncol; 2007 Aug; 106(2):407-12. PubMed ID: 17561234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Significance of progesterone receptor-A and -B expressions in endometrial adenocarcinoma.
    Miyamoto T; Watanabe J; Hata H; Jobo T; Kawaguchi M; Hattori M; Saito M; Kuramoto H
    J Steroid Biochem Mol Biol; 2004 Oct; 92(3):111-8. PubMed ID: 15555905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression.
    Sivridis E; Giatromanolaki A; Koukourakis M; Anastasiadis P
    Virchows Arch; 2001 May; 438(5):470-7. PubMed ID: 11407475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study.
    Köbel M; Atenafu EG; Rambau PF; Ferguson SE; Nelson GS; Ho TC; Panzarella T; McAlpine JN; Gilks CB; Clarke BA; Bernardini MQ
    Gynecol Oncol; 2016 Jun; 141(3):559-563. PubMed ID: 27072807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
    Lax SF; Pizer ES; Ronnett BM; Kurman RJ
    Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endometrial Endometrioid Carcinoma Metastases Show Decreased ER-Alpha and PR-A Expression Compared to Matched Primary Tumors.
    Bartosch C; Monteiro-Reis S; Vieira R; Pereira A; Rodrigues M; Jerónimo C; Lopes JM
    PLoS One; 2015; 10(8):e0134969. PubMed ID: 26252518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Expression of estrogen and progesterone receptor subtypes in human endometrial carcinoma tissues].
    Liao QP; Wu C; Zheng H; Yu L
    Zhonghua Fu Chan Ke Za Zhi; 2005 Nov; 40(11):752-5. PubMed ID: 16324249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
    Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
    Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.